报价延迟最少15分钟:2025/07/21 07:33 EDT
盘前时段
|
||||
|
3.83 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.76
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.10/0.28
|
|
企业价值
1.23B
|
| 资产负债 |
|
每股账面净值
-0.19
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
285.50M
|
|
每股收益
0.58
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 07:33 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. |
